Abstract

ObjectivesIn OReO/ENGOT-ov38 (NCT03106987), maintenance olaparib rechallenge significantly improved progression-free survival (PFS) versus placebo in platinumsensitive relapsed ovarian cancer (PSROC), irrespective of BRCA1/BRCA2 mutation (BRCAm) status (BRCAm: hazard ratio [HR] 0.57,...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Older Adults with Acute Myeloid Leukemia (AML) Experience Improvement in Health-Related Quality of Life (HRQoL) Scores with Intensive Therapy: Prospective Study from ECOG-ACRIN (EA) E2906 Phase 3 Trial
James M Foran ... David F Claxton
Blood | VOL. 142
James M Foran, et. al.James M Foran ... David F Claxton
28 Nov 2023
Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial
Michael Friedlander ...
Lancet Oncology | VOL. 22
Michael Friedlander, et. al.Michael Friedlander ...
13 Apr 2021
Impact of pegylated liposomal doxorubicin (PLD) plus docetaxel (D) versus single-agent D on health-related quality of life (HRQOL) of patients with advanced breast cancer (BC) previously treated with neoadjuvant-adjuvant anthracycline
S A Tjulandin ... O I Balashova
Journal of Clinical Oncology | VOL. 27
S A Tjulandin, et. al.S A Tjulandin ... O I Balashova
20 May 2009
Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose-escalation study 1108.
Peter H O'Donnell ... Pralay Mukhopadhyay
Cancer | VOL. 126
Peter H O'Donnell, et. al.Peter H O'Donnell ... Pralay Mukhopadhyay
03 Oct 2019
View more papers

More From: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Paper Title
Journal
Date
Author
Predictive factors for adnexal involvement in endometrial cancer FIGO stage IIIA
Giorgia Dinoi ... Francesco Fanfani
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | VOL. -
Giorgia Dinoi, et. al.Giorgia Dinoi ... Francesco Fanfani
13 Jul 2024
Role of V-Y flap reconstruction in vulvar cancer patients: multicenter retrospective study
Violante Di Donato ... Giorgio Bogani
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | VOL. -
Violante Di Donato, et. al.Violante Di Donato ... Giorgio Bogani
13 Jul 2024
Higher incidence of venous thromboembolism associated with increasing lines of treatment in heavily treated ovarian cancer patients
Erika J Lampert ... Mariam M Alhilli
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | VOL. -
Erika J Lampert, et. al.Erika J Lampert ... Mariam M Alhilli
13 Jul 2024
Antibody–drug conjugate targeting folate receptor α: a new milestone in personalized medicine for high-grade serous ovarian cancer
Antonio Gonzalez-Martin
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | VOL. -
Antonio Gonzalez-MartinAntonio Gonzalez-Martin
10 Jul 2024
View more papers